Login to Your Account



Clinic Roundup


Monday, July 1, 2013

• Soligenix Inc., of Princeton, N.J., enrolled and treated all patients in a Phase I trial of SGX203 for pediatric Crohn's disease. The goal of the 24-subject study was to characterize the drug's pharmacokinetic and pharmacodynamic profile of the formulation.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription